Deprecated: Creation of dynamic property WhitelabelOptions::$_title is deprecated in /home/grassnews/public_html/wp-content/themes/zox-news/admin/admin-page.php on line 79
Design Automation Conference 2019 Exhibitor Profiles – GrassNews
Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Design Automation Conference 2019 Exhibitor Profiles

Published

on

Reading Time: 8 minutes

LAS VEGAS–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/56DAC?src=hash” target=”_blank”gt;#56DAClt;/agt;–The 56th Design Automation Conference runs June 2 – 6, 2019
at the Las Vegas Convention Center.

Business Wire is the official
news distribution partner
for DAC 2019. Exhibitor profiles from
the conference are listed below.

***
Company: Achronix Semiconductor Corporation
Booth: 861
Web: https://www.achronix.com
Achronix Semiconductor Corporation is a privately held, fabless
semiconductor corporation based in Santa Clara, California and
offers high-performance FPGA and embedded FPGA (eFPGA) solutions.
Achronix’s history is one of pushing the boundaries in the
high-performance FPGA market. Achronix offerings include
programmable FPGA fabrics, discrete high-performance and
high-density FPGAs with hardwired system-level blocks, datacenter
and HPC hardware accelerator boards, and best-in-class EDA software
supporting all Achronix products.
 
 
Company: AMIQ EDA srl.
Booth: 854
Web: www.dvteclipse.com
AMIQ EDA provides tools – DVT Eclipse IDE, DVT Debugger Add-On,
Verissimo Linter, and Specador Documentation Generator – that enable
design and verification engineers increase the speed and quality of
new code development, simplify legacy code maintenance, accelerate
language and methodology learning, and improve source code
reliability. Working with 100+ companies in 30+ countries, AMIQ EDA
is recognized for its high quality products and customer service
responsiveness.
 
 
Company: AnaGlobe Technology, Inc.
Booth: 934
Web: http://www.anaglobe.com
AnaGlobe is a Taiwanese EDA company, has 2 major layout platforms,
THUNDER & GOLF. THUNDER is a versatile layout integration platform
to support heavy layout handling efforts from post P&R, IP merge
automation & management, physical ECO verification (LVL,
connectivity, etc.), DRC/LVS debugging interface, and even (in-line
inspection) defect-to-layout mapping, failure analysis and
chip-package integration (fanout, interposer and substrate routing,
pins connectivity, etc.).
 
GOLF is a custom layout platform with a simple yet GUI-mode powerful
PCell Designer for diversified applications. PCells are easily
created, previewed and debugged by PCell Designer.
 
AnaGlobe differentiates product to satisfy specific and individual
user requests.
 
 
Company: Breker Verification Systems
Booth: 611
Web: https://brekersystems.com/
Breker Verification Systems will demonstrate at DAC its portfolio of
Portable Stimulus solutions, a standard means to specify
verification intent and behaviors reusable across target platforms.
Demos will highlight how a graph-based verification and the
synthesis approach enables development of powerful test sets from
abstract scenario models. Its Trek Portable Stimulus Portfolio is
Graph-based to make complex scenarios comprehensible, Portable,
eliminating test redundancy across the verification process, and
Shareable to foster team communication and reuse. Intelligent
Testbench tools and apps allows synthesis of high-coverage, powerful
test cases for deployment into a variety of UVM to SoC verification
environments.
 
DAC attendees can schedule demonstrations at
https://brekersystems.com/dac/.
 
 
Company: Cadence Design Systems, Inc.
Booth: 915
Ticker Symbol & Exchange: NASDAQ: CDNS
Web: www.cadence.com
Cadence enables electronic systems and semiconductor companies to
create the innovative end products that are transforming the way
people live, work and play. Cadence software, hardware and
semiconductor IP are used by customers to deliver products to market
faster. The company’s System Design Enablement strategy helps
customers develop differentiated products—from chips to boards to
systems—in mobile, consumer, cloud datacenter, automotive,
aerospace, IoT, industrial and other market segments. Cadence is
listed as one of Fortune Magazine’s 100 Best Companies to Work For.
Learn more at cadence.com.
 
 
Company: Coventor, A Lam Research Company
Booth: 835
Web: www.coventor.com
Coventor® is the market leader in automated solutions for developing
semiconductor process technology, as well as micro-electromechanical
systems (MEMS). Coventor serves a worldwide customer base of
integrated device manufacturers, memory suppliers, fabless design
houses, independent foundries, and R&D organizations. Its
SEMulator3D modeling and analysis platform is used for fast and
accurate ‘virtual fabrication’ of advanced manufacturing processes,
allowing engineers to understand manufacturing effects early in the
development process and reduce time-consuming and costly silicon
learning cycles. Its CoventorMP MEMS design platform is used to
develop MEMS-based products for automotive, aerospace, industrial,
defense, and consumer electronics applications. The company is
headquartered in Cary, North Carolina, with development and sales
offices worldwide.
 
 
Company: Defacto Technologies
Booth: 667
Web: www.defactotech.com
After a first success on moving traditional DFT checks to RTL,
Defacto shifted its focus, 10 years ago, on providing SoC design
solutions to help reaching aggressive PPA requirements
cost-effectively. Defacto has proven the effectiveness of STAR as a
design platform for large SoCs.
 
By adopting Defacto’s STAR design solutions, major semiconductor
companies are continuously moving from traditional and painful SoC
design tasks to the Defacto’s joint “Build & Signoff” design
methodology. The related ROI has been proven for hundreds of
projects.
 
 
Company: Design And Reuse
Booth: 329
Web: https://www.design-reuse.com,
http://www.design-reuse-embedded.com, www.design-reuse.cn
Founded in 1997, D&R became the worldwide leader as a B2B portal in
the IP/SoC field with its community of 42,000 registered users,
75,000 Absolute Unique Visitors/Month, 18,000 daily updated IP/SOC
products, and news broadcast to 27,000 subscribers.
 
Based on more than 20 years experience, D&R sells IPMSTM: a Java/XML
multi-application, configurable platform, offering a comprehensive
solution for IP management including smart IP delivery and smart
computerized contract support, as well as an unique intelligent
software tool license management solution providing user behavior
profiling, and cost sharing, leading to well informed business
decision making.
 
 
Company: EDDR Software
Booth: 633
Web: www.eddrs.com
EDDR Software is a company that works with customers and partners in
order to help ENGINEER, DESIGN, DEVELOP, and RESEARCH solutions for
barriers created by technology and software in their business. EDDRS
also helps bridge gaps that may arise with changing technologies and
requirements. EDDRS has tools to help clients produce products for
their customers more efficiently and with higher performance. Check
out some of them at https://www.eddrs.com/pg/products.
 
 
Company: Faraday Technology Corporation
Booth: 1012
Ticker Symbol & Exchange: TWSE: 3035
Web: https://www.faraday-tech.com
Faraday Technology Corporation (TWSE: 3035) is a leading fabless
ASIC and silicon IP provider. From specification level to GDSII-in,
our flexible business engagement model allows customers to check-in
at various design phases in maximizing ASIC implementation
efficiency.
 
Faraday’s comprehensive IP portfolio and best-in-class IP
customization service have enabled customers’ products to address
various applications and market segments effortlessly.
 
Since 1993, Faraday has been cooperating with top-tier suppliers of
IP, EDA, manufacturing, packaging, and testing, completing more than
2,200 tapeouts resulting in hundreds of millions chips shipped
worldwide a year.
 
 
Company: Menta
Booth: 626
Web: www.menta-efpga.com
For ASIC and SoCs designers who need fast, right-the-first time
design and fast time to volume, Menta is the proven eFPGA pioneer
whose design-adaptive standard cells based architecture and
state-of-the-art tool set provides the highest degree of design
customization, best-in-class testability and fastest time-to-volume
for SoC design targeting any production node at any foundry.
 
 
Company: OneSpin Solutions
Booth: 308
Web: www.onespin.com
OneSpin will feature at DAC its full complement of certified IC
integrity verification solutions for building functionally correct,
safe, secure and trusted integrated circuits. Solutions are based on
OneSpin’s widely used formal verification technology and assure the
integrity of SoCs, ASICs and FPGAs. Partners include leaders
worldwide in automotive and industrial applications; defense;
avionics; artificial intelligence and machine learning; consumer
electronics; and communications. Its advanced solutions are
well-suited for developing heterogeneous computing platforms, using
programmable logic, and designing and integrating processor cores,
such as RISC-V. OneSpin’s customer-oriented commitment is
fundamental to its growth and success.
 
Connect with OneSpin at:
Twitter: https://twitter.com/OneSpinSolution
LinkedIn: https://www.linkedin.com/company/onespin-solutions
Facebook: https://www.facebook.com/OneSpinSolutions
 
 
Company: OpenText
Booth: 1117
Ticker Symbol & Exchange: OTEX NASDAQ
Web: https://www.opentext.com/
OpenText Connectivity products, formerly Hummingbird provides
web-based remote access and virtual desktop infrastructure (VDI)
software for UNIX, Linux and Windows applications.
 
OpenText Exceed TurboX (ETX) is designed from the ground up to
enable session resilience and local-like responsiveness for
graphically demanding applications, even over high latency WAN
connections.
 
Many leading semiconductor companies are successfully using ETX to
achieve blazing fast access from anywhere to chip layout
applications and other EDA tools.
 
 
Company: PRO DESIGN Electronic GmbH
Booth: 635
Web: https://www.profpga.com/
PRO DESIGN is a leading provider of FPGA-based Prototyping systems.
PRO DESIGN’s product family proFPGA is a very flexible
high-performance FPGA system which is mainly used for ASIC
Prototyping and pre-silicon software development. The modular
concept of the proFPGA system, consisting of different motherboards,
FPGA modules, daughter boards and interconnects allows the user to
adjust it for almost any type of application. PRO DESIGN is offering
FPGAs produced by XILINX and Intel, those can be Mix and Matched on
one proFPGA System.
 
 
Company: SANKALP SEMICONDUCTOR
Booth: 510
Web: www.sankalpsemi.com
Sankalp Semiconductor offers an integrated portfolio of services and
solutions to its customers in key semiconductor domains including
analog & mixed signal, digital, high-speed physical interface IP,
Embedded Memory Compiler, IOs & EDA modeling. Sankalp is a preferred
semiconductor design service partners to multiple Fortune 500
companies in the Automotive, Consumer, Networking, Wireless, IoT,
Medical electronics & Foundry space. The company enables its
customers deliver first time right silicon & engage with product
engineering teams across the globe to design SoCs. Sankalp is based
in Palo Alto, California & Hubli, India with offices in USA, India,
Canada, Germany, Malaysia and Japan.
 
 
Company: Sigasi
Booth: 646
Web: www.sigasi.com
Sigasi radically redefines digital design. Our design entry tool
Sigasi Studio drastically improves hardware designer productivity by
helping to write, inspect and modify digital circuit designs in the
most intuitive way. Advanced features such as intelligent
autocompletes and code refactoring, make VHDL, Verilog and
SystemVerilog design easier, more efficient.
 
Sigasi, has formed partnerships with FPGA and EDA companies
including Altera, Xilinx and Aldec. The Sigasi Studio XL platform is
used worldwide by industry leaders in the fields of healthcare,
consumer electronics, industrial automation, telecom, aerospace and
defense.
 
 
Company: Silicon Creations
Booth: 525
Web: www.siliconcr.com
Silicon Creations is focused on providing world-class silicon
intellectual property (IP) for precision and general-purpose timing
(PLLs), SerDes and high-speed differential I/Os. Silicon Creations’
IP is in production from 7 to 180-nanometer process technologies.
With a complete commitment to customer success, its IP has an
excellent record of first silicon to mass production in customer
designs. Silicon Creations, founded in 2006, is self-funded and
growing. The company has development centers in Atlanta, Ga., and
Krakow, Poland, and worldwide sales representation. For more
information, visit www.siliconcr.com.
 
 
Company: SmartDV Technologies
Booth: 514
Web: www.Smart-DV.com
SmartDV™ Technologies, the Proven and Trusted choice for
Verification Intellectual Property (VIP), will be in DAC Booth #514
with demonstrations of Smart ViPDebug™, its new protocol debugger
that reduces debug time by rapidly identifying violations. Also
highlighted will be SmartDV’s Compute Express Link (CXL) and
Ethernet Time-Sensitive Networking (TSN) VIP solutions, along with
its extensive VIP portfolio used in hundreds of networking, storage,
automotive, bus, MIPI and display chip projects. SmartDV’s VIP is
compatible with all verification languages, platforms and
methodologies supporting all simulation, emulation and formal
verification tools used in a coverage-driven chip design
verification flow.
 
DAC attendees can schedule demonstrations through SmartDV’s online
scheduler: http://smart-dv.com/dac.html.
 
 
Company: Univa
Booth: 1233
Web: www.univa.com
Univa is the leading innovator of workload management solutions that
optimize throughput and performance of applications, containers, and
services. Univa manages workloads automatically by maximizing shared
resources and enabling enterprises to scale compute resources across
on-premise, hybrid and cloud infrastructures. Univa’s solutions help
hundreds of companies to manage thousands of applications and run
billions of tasks every day to obtain actionable insights and
achieve faster time-to-results. Univa is headquartered in Chicago,
with offices in Canada and Germany.
 
 
Company: Verific Design Automation
Booth: 638
Web: www.verific.com
At DAC, Verific will celebrate 20 years as the leading provider of
SystemVerilog, Verilog, VHDL and UPF Parser Platforms, used by EDA,
FPGA and semiconductor companies worldwide. Verific’s R&D and
applications staff will explain how its SystemVerilog, VHDL and UPF
parsers, as well as its “Verific with INVIO” platform enable project
groups to develop advanced EDA products quickly and cost
effectively. Demos of the INVIO platform will illustrate the ways in
which its SystemVerilog- and VHDL-language agnostic Python and C++
APIs simplify and streamline a Verific user’s design environment to
accelerate tool development.
 
Engage with Verific at:
Email: info@verific.com
LinkedIn: https://www.linkedin.com/company-beta/810695

***

Qualified members of the press please note the following important
information.

Advertisement
Stake.com

Exhibitor News:
http://www.tradeshownews.com/events/design-automation-conference-2019/

Press Information:
https://dac.com/content/press-registration

About Business Wire

Business Wire, a Berkshire
Hathaway
 company, is the global leader in news
release distribution
and regulatory
disclosure
. Investor relations, public relations, public policy and
marketing professionals rely on Business Wire for secure and accurate
distribution of market-moving news and multimedia. Founded in 1961,
Business Wire is a trusted source for news organizations, journalists,
investment professionals, and regulatory authorities, delivering news
directly into editorial systems and leading online news sources via its
multi-patented NX Network. Business Wire has 18 newsrooms worldwide to
meet the needs of communications professionals and news media.

Learn more at www.businesswire.com.
Follow us on Twitter @businesswire.

Advertisement
Stake.com

Contacts

Jim Liebenau
+1.310.820.9473
Twitter: @tradeshownews


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Submits Investigational New Animal Drug Application to FDA’s Veterinary Center

Published

on

innocan-pharma-submits-investigational-new-animal-drug-application-to-fda’s-veterinary-center

HERZLIYA, Israel and CALGARY, AB, July 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA’s Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver and assigned an Investigational New Animal Drug (INAD) number for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product. This represents a significant step for the Company, as an INAD designation facilitates correspondence and data exchange with CVM to support LPT-CBD development as a new veterinary drug.

 

 

The Company further announced that following the assessment of LPT-CBD’s scientific package, the CVM recognized Innocan’s contribution to pursuing innovative animal drug products and technology and granted the company a sponsor fee waiver for fiscal year 2024.  

Innocan’s LPT-CBD is a proprietary drug delivery platform designed to provide prolonged-release CBD for chronic pain and well-being management in animals. Over the past year, repeated administration of LPT-CBD in dogs and other animals has demonstrated both efficacy and tolerability, providing sufficient evidence for the INAD application.

Advertisement
Stake.com

“We are thrilled by CVM’s response,” said Prof. Chezy Barenholz, CSO of Innocan Pharma. “The granted INAD will allow us to advance the investigational studies of LPT-CBD and share knowledge to support future discussions with CVM on LPT-CBD’s development plan. Moreover, the fee waiver, granted by CVM, supports our development and pursuit of innovative animal drug products and technology, further validating our approach and potential impact in veterinary medicine.”

Dr. Eyal Kalo, R&D Director at Innocan, added, “LPT-CBD is a unique technology that has proven itself worthy of the INAD fee waiver granted by CVM. This will streamline our efforts to deliver a unique solution for chronic pain management to the animal market.”

About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com 

Advertisement
Stake.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Advertisement
Stake.com

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-submits-investigational-new-animal-drug-application-to-fdas-veterinary-center-302207435.html

Continue Reading

Cannabis

Verano Announces the Opening of Zen Leaf Fairless Hills, the Company’s Newest Affiliated Dispensary in Pennsylvania, in Prime New Location

Published

on

  • Zen Leaf Fairless Hills, the Company’s newest affiliated dispensary in Pennsylvania, relocated from its former home in Chester to 203 Lincoln Highway, a busy thoroughfare with daily traffic of over 17,000 vehicles per day1
  • As the first medical cannabis dispensary in the city, Zen Leaf Fairless Hills will offer an elevated experience for area patients, including increased convenience and accessibility with numerous point-of-sale stations and kiosks for seamless in-store browsing and ordering
  • Verano’s active operations span 13 states, comprised of 142 dispensaries and 13 cultivation and processing facilities with more than 1 million square feet of cultivation capacity

CHICAGO, July 26, 2024 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the opening of Zen Leaf Fairless Hills in Pennsylvania on Friday, July 26th, following a ceremonial ribbon cutting at 11 a.m. local time. Zen Leaf Fairless Hills is located at 203 Lincoln Highway and will be open Monday through Saturday from 9 a.m. to 8 p.m. and Sunday from 10 a.m. to 6 p.m. local time.

The dispensary is located in Bucks County, the fourth largest county in the Commonwealth with a total population of over 630,0002 residents. To increase accessibility and convenience, Zen Leaf Fairless Hills features large in-store kiosks and numerous point-of-sale stations to enhance the browsing and ordering experience for patients. To celebrate the grand opening of Zen Leaf Fairless Hills and following a ceremonial ribbon cutting, patients will be greeted with complimentary deals and doorbusters on featured branded products.

“We are excited to bring the Zen Leaf experience to local patients in Fairless Hills, where our talented team members will continue to deliver hospitality-driven care and top-quality products for local patients,” said George Archos, Verano Founder and Chief Executive Officer. “As the Pennsylvania medical cannabis patient population continues to grow, we are grateful for the opportunity to deepen our roots in Bucks County at our newest Zen Leaf location in the Commonwealth, and look forward to providing a warm and welcoming environment for current and future patients.”

Zen Leaf Fairless Hills adds another convenient outlet for Philadelphia area patients, and solidifies Verano’s footprint in the state as one of the Company’s 18 affiliated Pennsylvania dispensaries. Verano’s Pennsylvania operations also include a state-of-the-art 62,000 square foot cultivation and processing facility in Chester, where the Company produces its signature Verano Reserve flower and Troches, concentrates and vapes; (the) Essence and Savvy flower and extracts; and Avexia RSO cannabis oil and topicals. For additional convenience and accessibility, patients can choose to order ahead at ZenLeafDispensaries.com for express in-store pickup.

About Verano

Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF), one of the U.S. cannabis industry’s leading companies based on historical revenue, geographic scope and brand performance, is a vertically integrated, multi-state operator embracing a mission of saying Yes to plant progress and the bold exploration of cannabis. Verano provides a superior cannabis shopping experience in medical and adult use markets under the Zen Leaf and MÜV dispensary banners, including Cabbage Club, an innovative annual membership program offering exclusive benefits for cannabis consumers. Verano produces a comprehensive suite of high-quality, regulated cannabis products sold under its diverse portfolio of trusted consumer brands including Verano, (the) Essence, MÜV, Savvy, BITS, Encore, and Avexia. Verano’s active operations span 13 U.S. states, comprised of 13 production facilities with over 1,000,000 square feet of cultivation capacity. Learn more at Verano.com.

Advertisement
Stake.com

Contacts:

Media
Verano
Steve Mazeika
VP, Communications
Steve.Mazeika@verano.com

Investors
Verano
Julianna Paterra, CFA
VP, Investor Relations
Julianna.Paterra@verano.com

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans, strategies, or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “projects,” “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, its quarterly report on Form 10-Q for the quarter ended March 31, 2024 and any subsequent quarterly reports on Form 10-Q, in each case, filed with the U.S. Securities and Exchange Commission at www.sec.gov. The Company makes no assurances and cannot predict the outcome of all or any part of the on-going litigation with Goodness Growth referenced in this press release, including whether the Company will prevail on its Notice of Application and its counterclaim, or whether Goodness Growth will prevail on its claim for damages against the Company. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Advertisement
Stake.com

###


1 Pennsylvania Department of Transportation
2 United States Census Bureau

Continue Reading

Cannabis

Unlocking New Horizons in Health: TNR, The Niche Research Reveals the Transformative Power of Minor Cannabinoids

Published

on

Wilmington, Delaware, July 25, 2024 (GLOBE NEWSWIRE) — Minor cannabinoids refer to the lesser-known compounds found in the cannabis plant, distinct from the well-known THC (tetrahydrocannabinol) and CBD (cannabidiol). While THC and CBD dominate the market, minor cannabinoids such as CBG (cannabigerol), CBC (cannabichromene), and CBN (cannabinol) are gaining attention for their potential therapeutic benefits. These compounds are extracted from both marijuana and hemp plants, with varying legal restrictions depending on their THC content. The minor cannabinoids market is poised for significant growth, driven by increasing consumer awareness and demand for alternative health and wellness products. As regulatory environments around cannabis products evolve, companies are exploring the potential of minor cannabinoids in various applications, including pharmaceuticals, nutraceuticals, cosmetics, and food and beverages.

Minor cannabinoids are being researched for their potential therapeutic effects, including anti-inflammatory, analgesic, and neuroprotective properties. This versatility facilitates product diversification in various industries. Companies are investing in research and development to create novel formulations and delivery methods for minor cannabinoids. This includes nano-emulsions, encapsulation technologies, and controlled-release systems to enhance bioavailability and efficacy. For example, in January 2022, CBDA + CBGA Tincture a new product was launched by Hometown Hero CBD. This 30ml tincture contains 600mg each of CBGA, CBDA, CBG, and CBD. Derived from hemp, the cannabinoids in this tincture comply with legal requirements across all 50 states in the USA. There is an increasing consumer preference for natural as well as plant-based remedies, which in turn is driving the demand for cannabinoid-infused products. This trend is particularly strong among younger demographics seeking alternatives to traditional pharmaceuticals. Evolving regulatory frameworks, particularly in regions like North America and Europe, are creating opportunities for legal market expansion. Regulatory clarity is crucial for market participants to navigate compliance and market entry.

Global Minor Cannabinoids Market: Key Datapoints
 

Market Value in 2023

Advertisement
Stake.com
 

US$ 17.8 Bn

 

Market Value Forecast by 2034

 
Advertisement
Stake.com

US$ 42.3 Bn

 

Growth Rate

 

 
Advertisement
Stake.com

8.2%

 

Historical Data

 

 
Advertisement
Stake.com

2016 – 2022

 

Base Year

 

 
Advertisement
Stake.com

2023

 

Forecast Data

 

 
Advertisement
Stake.com

2024 – 2034

Increasing consumer interest in health and wellness products, coupled with the perceived therapeutic benefits of cannabinoids, is a major driver of market growth. Progressive cannabis legalization in various parts of the world, including the United States and parts of Europe, is expanding the addressable market for minor cannabinoids. Significant investments in research and development by pharmaceutical and biotechnology companies are accelerating product innovation and clinical trials. The market remains fragmented with opportunities for new entrants and niche players to introduce specialized products catering to specific consumer needs.

Get Sample Copy of the Report

The COVID-19 pandemic initially disrupted supply chains and retail channels for minor cannabinoids products. However, the crisis also underscored the importance of health and wellness, leading to increased interest in natural remedies, including cannabinoids. As economies recover, the market is expected to rebound stronger.

The geopolitical tensions, such as the Russia-Ukraine conflict, have also affected global markets, including the minor cannabinoids sector. Fluctuating currency values, supply chain disruptions, and geopolitical uncertainty have impacted production and distribution channels. However, the long-term impact will depend on geopolitical developments and their influence on global trade and regulatory environments.

Advertisement
Stake.com

The minor cannabinoids market presents significant opportunities for growth and innovation, driven by evolving consumer preferences, regulatory advancements, and expanding research initiatives. Companies that can navigate regulatory complexities, invest in research and development, and respond to shifting consumer trends are well-positioned to capitalize on this emerging market. As the market matures, collaboration across sectors and regions will be crucial in unlocking the full potential of minor cannabinoids in various industries worldwide.

Visit our Homepage

Global Minor Cannabinoids Market: Key Takeaways of the Report

  • Cannabigerol (CBG) segment by product type is expected to grow at a CAGR of 6.7% in the minor cannabinoids market due to increasing research highlighting its potential therapeutic benefits, including anti-inflammatory, antimicrobial, and neuroprotective properties. As consumer awareness grows and regulatory environments become more favorable, there is heightened interest in CBG-based products for their diverse health applications, ranging from skincare to pharmaceutical formulations, driving sustained market demand and expansion.
  • Pharmaceutical segment by application, leads the minor cannabinoids market with a significant revenue share of 35.8% owing to growing recognition of cannabinoids’ potential in therapeutic applications. Cannabinoids like CBD, CBG, and others show promise in treating conditions such as epilepsy, chronic pain, and anxiety disorders, backed by increasing clinical research and favorable regulatory developments. Pharmaceutical companies are investing heavily in cannabinoid-based drug development, driving market growth as they seek to capitalize on these compounds’ efficacy and market potential in addressing unmet medical needs.
  • In 2023, Latin America is anticipated as fastest growing region in the global minor cannabinoids market due to evolving regulatory landscapes favoring cannabis legalization and cultivation. This shift is fostering a burgeoning industry infrastructure for cannabis extraction and product development. Additionally, increasing consumer acceptance of cannabinoid-based products for medicinal and wellness purposes is driving market expansion. With a vast potential consumer base and supportive regulatory frameworks, Latin America presents significant growth opportunities for companies seeking to enter or expand within the minor cannabinoids market.

Key Development:

  • In December 2023, Rare Cannabinoid Company introduced Uplift Gummies infused with THC and THCV. These gummies combine the relaxing properties of Delta-9-THC with the energizing and appetite-controlling effects of CBD and THCV.
  • In October 2022, High Tide Inc., a cannabis retailer, announced that its Colorado-based subsidiary, NuLeaf Naturals, had launched plant-based softgels and full-spectrum multicannabinoid oil in Manitoba. The products feature CBC, CBD, CBG, Delta-9 tetrahydrocannabinol (Delta 9), and CBN.

Browse Related Category Reports

Global Minor Cannabinoids Market:

  • Aurora Europe GmbH
  • BulKanna
  • CBD. INC.
  • Fresh Bros Hemp Company
  • GCM Holdings, LLC (Global Cannabinoids)
  • GenCanna.
  • High Purity Natural Products.
  • Laurelcrest
  • Mile High Labs
  • PBG Global
  • Rhizo Sciences
  • ZERO POINT EXTRACTION, LLC
  • Other Industry Participants

Global Minor Cannabinoids Market

By Product Type

Advertisement
Stake.com
  • Cannabigerol (CBG)
  • Cannabichromene (CBC)
  • Cannabinol (CBN)
  • Cannabidivarin (CBDV)
  • Tetrahydrocannabutol (THCB)
  • Tetrahydrocannabivarin (THCV)
  • Tetrahydrocannabiphorol (THCP)
  • Others

By Application

  • Pharmaceutical
    • Pain Management
    • Mental Health
    • Sleep Disorders
    • Anti-inflammatory
    • Others
  • Nutraceuticals
  • Cosmetics and Personal Care
  • Food and Beverages
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)  

Consult with Our Expert:

Jay Reynolds

The Niche Research

Japan (Toll-Free): +81 663-386-8111

South Korea (Toll-Free): +82-808- 703-126

Saudi Arabia (Toll-Free): +966 800-850-1643

Advertisement
Stake.com

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

Email: askanexpert@thenicheresearch.com

Website: www.thenicheresearch.com

Advertisement
Stake.com
Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: sales@hipther.agency

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania